Search research articles
Contact Us
Filters
Showing results (471-480 of 528) with videos related to
Page
of 53
Sort By:
Astrobiology
|
August 29, 2007
Searching for life on Mars: selection of molecular targets for ESA's aurora ExoMars mission
John Parnell, David Cullen, Mark R Sims, et al.
Pediatric Obesity
|
December 20, 2019
Parental adiposity differentially associates with newborn body composition
Eva C Diaz, Mario A Cleves, Marisha DiCarlo, et al.
Journal of Neuroscience Methods
|
February 24, 2022
In vivo MRI evaluation of anterograde manganese transport along the visual pathway following whole eye transplantation
Chiaki Komatsu, Yolandi van der Merwe, Lin He, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
April 13, 2021
Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Yolandi van der Merwe, Matthew C Murphy, Jeffrey R Sims, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 24, 2024
Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease
R A Rissman, M C Donohue, O Langford, et al.
The New England Journal of Medicine
|
March 15, 2021
Donanemab in Early Alzheimer's Disease
Mark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 17, 2014
Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models
R Zwart, E Sher, X Ping, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 24, 2024
Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial
R Raman, K Hussen, M C Donohue, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial
Lars L Raket, Ming Lu, Cynthia D Evans, et al.
Page
of 53
Search research articles
Search
Showing results (471-480 of 528) with videos related to
Sort By:
Page
of 53
Astrobiology
|
August 29, 2007
Searching for life on Mars: selection of molecular targets for ESA's aurora ExoMars mission
John Parnell, David Cullen, Mark R Sims, et al.
Pediatric Obesity
|
December 20, 2019
Parental adiposity differentially associates with newborn body composition
Eva C Diaz, Mario A Cleves, Marisha DiCarlo, et al.
Journal of Neuroscience Methods
|
February 24, 2022
In vivo MRI evaluation of anterograde manganese transport along the visual pathway following whole eye transplantation
Chiaki Komatsu, Yolandi van der Merwe, Lin He, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
April 13, 2021
Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Yolandi van der Merwe, Matthew C Murphy, Jeffrey R Sims, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 24, 2024
Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease
R A Rissman, M C Donohue, O Langford, et al.
The New England Journal of Medicine
|
March 15, 2021
Donanemab in Early Alzheimer's Disease
Mark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 17, 2014
Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models
R Zwart, E Sher, X Ping, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 24, 2024
Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial
R Raman, K Hussen, M C Donohue, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial
Lars L Raket, Ming Lu, Cynthia D Evans, et al.
Page
of 53